loader2
Login Open ICICI 3-in-1 Account

Dr Lal Pathlabs Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Dr. Lal Pathlabs Ltd. 31 Oct 2025 14:37 PM

Q2FY26 Quarterly Result Announced for Dr. Lal Pathlabs Ltd.

Healthcare Services company Dr. Lal Pathlabs announced Q2FY26 results

  • Revenue: Rs 731 crore compared to Rs 660 crore during Q2FY25, change 10.7%.
  • EBITDA: Rs 224 crore compared to Rs 202 crore during Q2FY25, change 10.8%.
  • EBITDA Margin: 30.7% for Q2FY26.
  • PBT: Rs 204 crore compared to Rs 183 crore during Q2FY25, change 11.2%.
  • PAT: Rs 152 crore compared to Rs 131 crore during Q2FY25, change 16.4%.

Brig Dr Arvind Lal, Executive Chairman, said: “At Dr. Lal PathLabs, we see this decade as one for deep transformation. The burden of chronic and lifestyle-related diseases continues to rise, demanding greater focus on early detection and continuous monitoring. As new therapies for diabetes, hypertension and obesity become more widely available, the role of diagnostics will only intensify.

Further, as policy initiatives like Ayushman Bharat expand access across Tier-2 and Tier-3 regions, diagnostics is emerging as the essential first step in care delivery. The growing awareness around preventive health, supported by rapid digital adoption, is helping millions of citizens engage with organized healthcare for the first time. This convergence of accessibility, affordability, and accountability marks a defining moment for the sector, and we are privileged to play a prime role in it.

As the shift from unorganized to organized healthcare continues, we stand ready to lead the way responsibly and to contribute meaningfully to India’s ambition of universal healthcare.”

Shankha Banerjee, Chief Executive Officer, said: “Q2FY26 marked a healthy revenue growth trajectory on the back of a robust sample volume growth. As we continue to focus on improving patient service, enhancing medical expertise and network expansion, this momentum is expected to continue.

We continue to broaden our high-complexity testing capabilities, including Genomics, Oncology, Autoimmunity and others. We are also increasing applications for AI in our operations, including inhouse developed algorithms.

Digital and automation initiatives remain central to improving operational efficiency, enhancing patient experience, and supporting scalable growth.

Moving forward, growth will be underpinned by geographic expansion, portfolio innovation and digital enablement. Our pricing discipline continues to serve as a powerful lever, and is expected to support movement from unorganized to organized players.

Our operational priority remains to maximize network utilization and convert infrastructure into significant operating leverage, ensuring we deliver superior, sustainable, and profitable growth for our shareholders.”

Ved Prakash Goel, Group CFO & CEO, said: “Q2FY26 demonstrated steady growth in volumes and favourable business mix, driving sustained financial performance. By maintaining disciplined execution, cost efficiency and a calibrated pricing approach, we have maintained profitability while retaining strategic flexibility for future investments.

During the quarter, we further expanded our footprint across underpenetrated markets, supported by new labs and PSCs, while reinforcing engagement with channel partners. This tiered expansion strategy, coupled with completion of back-end integration and merger of Suburban Diagnostics, is helping us unlock new demand pockets and strengthen our leadership in core regions, including Delhi NCR, Mumbai, Pune, and Goa. Strategic digital investments continue to yield tangible ROI.

Looking ahead, with a robust balance sheet, strategic investments in technology, and a clearly defined growth roadmap, we are confident of delivering sustainable longterm value and capturing the shift from unorganized to organized diagnostics across India.”

Result PDF

Healthcare Services company Dr. Lal Pathlabs announced Q1FY26 results

  • Revenue increased by 11.3% in Q1FY26 to Rs 670 crore.
  • EBITDA increased by 13.1% with a margin of 28.7%.
  • PAT increased by 24.3% to Rs 134 crore, with a margin for of 20.0%.
  • Interim Dividend of Rs 6 per share for Q1FY26.

Result PDF

Healthcare Services company Dr. Lal Pathlabs announced Q4FY25 results

  • Revenue: Rs 603 crore compared to Rs 545 crore during Q4FY24, change 10.5%.
  • EBITDA: Rs 169 crore compared to Rs 145 crore during Q4FY24, change 16.9%.
  • EBITDA margin: 28.1% for Q4FY25.
  • PAT: Rs 156 crore compared to Rs 86 crore during Q4FY24, change 81.4%.
  • PAT margin: 25.8% for Q4FY25.
  • Fourth Interim Dividend of Rs 6 per share for FY25.

Result PDF

Healthcare Services company Dr. Lal Pathlabs announced Q3FY25 results

  • Revenue increased by 10.7% from Rs 597 crore in Q3FY25 to Rs 539 crore in Q3FY24..
  • EBITDA increased by 9.6% from Rs 154 crore in Q3FY25 to Rs 141 crore in Q3FY24, with a margin of 25.8%.
  • PAT increased by 19.3% from Rs 98 crore in Q3FY25 to Rs 82 crore in Q3FY24, with a margin for of 16.4%.
  • Third Interim Dividend of Rs. 6 per share for FY25.

Result PDF

Healthcare Services company Dr. Lal Pathlabs announced Q2FY25 results

  • Revenue increased by 9.8% in Q2FY25, Rs 660 crore compared to Rs 601 crore during Q2FY24.
  • EBITDA increased by 13.9% with a margin of 30.7%.
  • PAT increased by 18.1% with a margin for of 19.8%.
  • Second Interim Dividend of Rs 6 per share for FY25

Result PDF

Healthcare Services company Dr. Lal Pathlabs announced Q1FY25 results:

  • Revenue increased by 11.3% in Q1FY25 to Rs 602 crore
  • EBITDA increased by 16.2% with a margin of 28.2%
  • PAT increased by 29.1% to Rs 108 crore with a margin for of 17.9%
  • Interim Dividend of Rs 6 per share for FY 2024-25 

Result PDF

Healthcare Services company Dr. Lal PathLabs announced Q4FY24 results:

  • Revenue increased by 11.1% in Q4FY24
  • EBITDA increased by 25.1% with a margin of 26.5%
  • PAT increased by 50.8% with a margin for of 15.7%

Result PDF

Healthcare Services company Dr. Lal Pathlabs announced Q3FY24 & 9MFY24 results:

Q3FY24:

  • Revenue: In Q3FY24, Dr Lal PathLabs reported a revenue of Rs 539 crore, marking a 10.1% increase from the Rs 489 crore recorded in Q3FY23.
  • Operating Expenditure: The operating expenditure rose by 5.8% to Rs 398 crore in the current quarter from Rs 376 crore in the corresponding quarter of the previous fiscal year.
  • EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization): The Company's EBITDA escalated significantly by 24.6%, amounting to Rs 141 crore as compared to Rs 113 crore in Q3FY23, resulting in an EBITDA margin of 26.1%.
  • Profit After Tax (PAT): PAT witnessed a substantial increase of 53.3% to Rs 82 crore in Q3FY24 from Rs 54 crore in Q3FY23, achieving a PAT margin of 15.3%.
  • Earnings per Share (EPS): EPS climbed up to Rs 9.8, reflecting a remarkable 53.2% gain over the Rs 6.4 reported in Q3FY23.

9MFY24:

  • Revenue: the Company's cumulative revenue reached Rs 1681 crore, which is a 10.2% increment year-on-year.
  • Operating Expenditure: operating expenditure increased by 5.6% to Rs 1217 crore.
  • EBITDA: EBITDA grew by 24.1% to Rs 465 crore, from Rs 374 crore with an improved margin of 27.6%.
  • Profit After Tax (PAT): The nine months ended December 31, 2023, saw PAT soar by 50.5% to Rs 277 crore.
  • Earnings per Share (EPS): EPS stood at Rs 32.9, an increase of 49.5% from the previous year.

 

 

 

 

Result PDF

Healthcare Services company Dr. Lal Pathlabs announced Q2FY24 results:


1. Financial Performance
- Total revenue of Rs 601 crore in Q2FY24, an increase of 12.6% compared to Q2FY23.
- Revenue excluding RTPCR increased by 14.4% in Q2FY24.
- EBITDA margin for Q2FY24 was 29.6%.
- PBT for Q2FY24 was Rs 152 crore.
- PAT for Q2FY24 was Rs 111 crore.
- PAT margin for Q2FY24 was 18.4%.
- The company's EPS for Q2FY24 was 13.2.

2. Operating Expenditure
- Operating Expenditure for Q2FY24 was Rs 424 crore.
- Operating Expenditure increased by 8.6% compared to Q2FY23.

3. Other Financial Highlights
- Other Income for Q2FY24 was Rs 18 crore.
- Depreciation cost for Q2FY24 was Rs 36 crore.
- Finance cost for Q2FY24 was Rs 8 crore.

 

 

Result PDF

Healthcare Services company Dr. Lal Pathlabs announced Q1FY24 results:

  • Revenue of Rs 541 crore in Q1FY24 compared to Rs 503 crore in Q1FY23, up 7.6% YoY
  • Non-Covid Revenue increased by 9.7% to Rs 528 crore in Q1FY24
  • Normalised EBITDA margin (after adjustment for stock-based compensation & CSR) for Q1FY24 is 28.4%
  • PAT margin for Q1FY24 is 15.4%

 

 

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app